Haplomics

Last updated: October 09, 2024

Malcolm Simons, Founder
Malcolm Simons, Founder
USA | Funding: $211.5M (+)

Website: http://www.haplomics.com/

Haplomics is a biotech company focused on the treatment and cure of hemophilia. Scientists at Haplomics are pursuing three promising initiatives to control and potentially eliminate this cruel disease: determining why 30% of hemophilia patients develop inhibitors to treatment; developing a new technique to overcome this allergic response; and repairing patients’ defective DNA, curing them for life.